Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended June 30, 2013, and highlighted progress in the development of its Toll-like receptor (TLR) antagonist programs.
“During the second quarter, we made progress on multiple fronts. We strengthened our financial position through a $16.5 million common stock offering.
Hey, check out all the research scientist jobs. Post your resume today!
